Adult refractory/relapsed B-cell lymphoma
Conditions
Interventions
Experimental group:Reinfusion cell
Sponsors
Beijing Boren Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1) Patients who have been diagnosed with B-cell lymphoma and have relapsed after treatment with second-line or higher regimens (standard treatment including Rituxan and high-dose chemotherapy, or half a year after autologous hematopoietic stem cell transplantation), autologous CART cell therapy is invalid or the disease has progressed; 2) Male or female patients, aged 18-60 years (including 18 years old); 3) No severe allergies; 4) Physical fitness score 0-2 points; 5) The estimated survival period >=90 days; 6) Tumor tissue immunohistochemistry CD19 and CD22 are positive for one of the antigens or both; 7) The donor can collect enough lymphocytes and hematopoietic stem cells; 8) The patient voluntarily signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1) Intracranial hypertension or brain consciousness disorder; 2) Symptomatic heart failure or severe arrhythmia; 3) Symptoms of severe respiratory failure; 4) With other types of malignant tumors; 5) Diffuse intravascular coagulation; 6) Serum creatinine and/or urea nitrogen >=1.5 ULN; 7) Suffer from sepsis or other infections that are difficult to control; 8) Suffer from uncontrollable diabetes; 9) Severe mental disorder; 10) There are obvious intracranial lesions in head MRI examination; 11) Have received organ transplantation (excluding autologous hematopoietic stem cell transplantation); 12) Female patients (patients with fertility) have a positive blood HCG test; 13) Active hepatitis (including positive copy number of hepatitis B DNA and hepatitis C RNA) and positive screening for AIDS and syphilis; 14) DSA (anti-donor specific antibody) is positive.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety evaluation index;Pharmacokinetic evaluation index;Curative effect evaluation index; | — |
Countries
China
Contacts
Public ContactTong Wu
Beijing Boren Hospital
Outcome results
None listed